{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T04:30:43Z","timestamp":1791779443065,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":5227,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1093\/annonc\/mdi279","type":"journal-article","created":{"date-parts":[[2005,7,13]],"date-time":"2005-07-13T08:04:35Z","timestamp":1121241875000},"page":"1425-1433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":460,"title":["Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors"],"prefix":"10.1016","volume":"16","author":[{"given":"S.","family":"Segaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdi279_bb0010","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/annonc\/mdh257","article-title":"Pharmacological background of EGFR targeting","volume":"15","author":"Castillo","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdi279_bb0020","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0025","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ijrobp.2003.09.098","article-title":"Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody","volume":"58","author":"Foon","year":"2004","journal-title":"Int J Radiation Oncology Biol Phys"},{"key":"10.1093\/annonc\/mdi279_bb0030","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2004.05.114","article-title":"Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor","volume":"22","author":"Vanhoefer","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0035","first-page":"S5","article-title":"A translational research study of ZD1839 at a dose of 750mg in patients with pretreated advanced or metastatic colorectal cancer: NCIC CTG IND.122","volume":"13","author":"Seymour","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0040","first-page":"196","article-title":"Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer","volume":"22","author":"Oza","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0045","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdi279_bb0050","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdi279_bb0055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1359-6349(04)80287-8","article-title":"Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin","volume":"2","author":"Van Cutsem","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdi279_bb0060","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0065","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0070","first-page":"2478","article-title":"Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients","volume":"9","author":"Malik","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdi279_bb0075","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","article-title":"ZD1839, a selective oral epidermal growth factor receptor\u2014tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial","volume":"20","author":"Ranson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0080","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0085","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1200\/JCO.2004.08.189","article-title":"Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor","volume":"22","author":"Tan","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0090","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2004.11.061","article-title":"Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer","volume":"22","author":"Rowinsky","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0095","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0100","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0. http:\/\/www.ctep.cancer.gov\/reporting\/ctc.html."},{"key":"10.1093\/annonc\/mdi279_bb0105","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archderm.138.1.129","article-title":"Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors","volume":"138","author":"Kimyai-Asadi","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0115","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","article-title":"Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor","volume":"147","author":"Van Doorn","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0120","first-page":"443","article-title":"Eruptions acn\u00e9iformes induites par le c\u00e9tuximab","volume":"130","author":"Walon","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"10.1093\/annonc\/mdi279_bb0125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2230.2004.01466.x","article-title":"Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor","volume":"29","author":"Fernandez-Galar","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1093\/annonc\/mdi279_bb0135","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","article-title":"Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours","volume":"151","author":"Jacot","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0140","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.2005.04.057","article-title":"Practical management of patients with non-small-cell lung cancer treated with gefitinib","volume":"23","author":"Shah","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0145","series-title":"Acne and rosacea","author":"Plewig","year":"2000"},{"key":"10.1093\/annonc\/mdi279_bb0150","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2002.124621","article-title":"Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody","volume":"45","author":"Boucher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0155","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000073100","article-title":"Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor","volume":"207","author":"Dainichi","year":"2003","journal-title":"Dermatology"},{"key":"10.1093\/annonc\/mdi279_bb0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1346-8138.2003.tb00387.x","article-title":"Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor","volume":"30","author":"Nakano","year":"2003","journal-title":"J Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0165","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","article-title":"Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Chang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0170","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/02841860310006038","article-title":"Epidermal growth factor receptor inhibition induces trichomegaly","volume":"42","author":"Dueland","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0175","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2004.06265.x","article-title":"Trichomegaly following treatment with gefitinib (ZD1839)","volume":"151","author":"Pascual","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0180","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0185","first-page":"204","article-title":"The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies","volume":"22","author":"Saltz","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 12","key":"10.1093\/annonc\/mdi279_bb0190","first-page":"23","article-title":"Can rash associated with HER1\/EGFR inhibition be used as a marker of treatment outcome?","volume":"11","author":"Perez-Soler","year":"2003","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdi279_bb0195","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/annonc\/mdi157","article-title":"Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small-cell lung cancer","volume":"16","author":"Mohamed","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0200","first-page":"2389","article-title":"Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough?","volume":"9","author":"Baselga","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdi279_bb0205","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.1158\/0008-5472.CAN-04-1036","article-title":"An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors","volume":"64","author":"Amador","year":"2004","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdi279_bb0210","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1126\/science.7618084","article-title":"Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype","volume":"269","author":"Threadgill","year":"1995","journal-title":"Science"},{"key":"10.1093\/annonc\/mdi279_bb0215","first-page":"1959","article-title":"Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development","volume":"150","author":"Hansen","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdi279_bb0220","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0733-8635(05)70237-0","article-title":"DiGiovanna. Systemic retinoid therapy","volume":"19","year":"2001","journal-title":"Dermatol Clin"},{"key":"10.1093\/annonc\/mdi279_bb0225","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/1523-1747.ep12276708","article-title":"Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition","volume":"85","author":"Green","year":"1985","journal-title":"J Invest Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0230","first-page":"505","article-title":"The EGF receptor\u2014an essential regulator of multiple epidermal functions","volume":"10","author":"Jost","year":"2000","journal-title":"Eur J Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0235","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition","volume":"20","author":"Albanell","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi279_bb0240","doi-asserted-by":"crossref","first-page":"37285","DOI":"10.1074\/jbc.274.52.37285","article-title":"Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes","volume":"274","author":"Wakita","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1093\/annonc\/mdi279_bb0245","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000017862","article-title":"Modelling the infundibulum in acne","volume":"196","author":"Guy","year":"1998","journal-title":"Dermatology"},{"key":"10.1093\/annonc\/mdi279_bb0250","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0002-9440(10)63654-1","article-title":"Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation","volume":"163","author":"Mascia","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1093\/annonc\/mdi279_bb0255","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000078818","article-title":"New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation","volume":"17","author":"Mimeault","year":"2004","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1093\/annonc\/mdi279_bb0260","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1002\/j.1460-2075.1995.tb00206.x","article-title":"Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure","volume":"14","author":"Murillas","year":"1995","journal-title":"EMBO J"},{"key":"10.1093\/annonc\/mdi279_bb0265","first-page":"313","article-title":"Targeted expression of activated erbB-2 to the epidermis of transgenic mice elicits striking developmental abnormalities in the epidermis and hair follicles","volume":"9","author":"Xie","year":"1998","journal-title":"Cell Growth Differ"},{"key":"10.1093\/annonc\/mdi279_bb0270","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1038\/sj.onc.1203778","article-title":"Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development","volume":"19","author":"Kiguchi","year":"2000","journal-title":"Oncogene"},{"key":"10.1093\/annonc\/mdi279_bb0275","first-page":"1","article-title":"Lung cancer prevention: retinoids and the epidermal growth factor receptor\u2014a phoenix rising?","volume":"8","author":"Averbuch","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdi279_bb0280","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2230.1986.tb00439.x","article-title":"Etretinate and the nails (study of 130 cases): possible mechanisms of some side-effects","volume":"11","author":"Baran","year":"1986","journal-title":"Clin Exp Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0285","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1080\/000155599750009834","article-title":"Increased expression of vascular endothelial growth factor in pyogenic granulomas","volume":"79","author":"Bragado","year":"1999","journal-title":"Acta Derm Venereol"},{"key":"10.1093\/annonc\/mdi279_bb0290","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1523-1747.1998.00393.x","article-title":"Retinoids downregulate vascular endothelial growth factor\/vascular permeability factor production by normal human keratinocytes","volume":"111","author":"Weninger","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.1093\/annonc\/mdi279_bb0295","first-page":"257","article-title":"Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice","volume":"5","author":"Perrotte","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdi279_bb0300","first-page":"316","article-title":"Management of acneiform rashes related to gefitinib therapy","volume":"8","author":"Purdom","year":"2004","journal-title":"Clin J Oncol Nurs"},{"key":"10.1093\/annonc\/mdi279_bb0305","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatological side effects associated with gefitinib therapy: clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"issue":"Suppl","key":"10.1093\/annonc\/mdi279_bb0310","article-title":"Management of cutaneous adverse effects during treatment with ZD1838 in advanced non-small cell lung cancer (NSCLC) surprising efficacy of early local treatment","volume":"22","author":"Cortesi","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419549869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419549869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/16\/9\/1425\/434749\/mdi279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:41:57Z","timestamp":1760334117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419549869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0923753419549869"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdi279","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/annonc\/mdi279","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}